Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2077 studies found for:    "Acute non lymphoblastic leukemia"
Show Display Options
Rank Status Study
1 Completed Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years
Condition: Acute Myeloblastic Leukaemia
Interventions: Drug: ARA-C;   Drug: Idarubicin;   Drug: Leucomax
2 Recruiting Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Interventions: Drug: Azacitadine;   Drug: Fludarabine;   Drug: Cytarabine;   Drug: Lenograstim;   Drug: Filgastrim
3 Unknown  Idarubicin Overcomes MDR1 Induced Chemoresistance With Higher Induction Remission Rate and Quality Than Daunorubicin in Acute Myeloid Leukemia Patients
Condition: Acute Myeloid Leukemia
Intervention: Drug: Idarubicin
4 Recruiting Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Conditions: Relapsed Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
Intervention: Drug: cabozantinib
5 Unknown  Extension Study With Tosedostat in Relapsed/Refractory Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Intervention: Drug: CHR-2797
6 Not yet recruiting Interleukin-21 (IL-21)- Expanded Natural Killer Cells for Induction of Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Intervention: Biological: NK Cells + Chemotherapy Starting
7 Completed Role of PTK-7 in Acute Myeloid Leukemias
Condition: Acute Myeloid Leukemia
Interventions: Other: Bone marrow aspiration;   Other: Blood sampling
8 Completed A Phase I Study of OCV-501 in Acute Myeloid Leukemia Patients
Condition: Acute Myeloid Leukemia
Intervention: Drug: OCV-501
9 Terminated
Has Results
Cytarabine in Combination With Arsenic Trioxide vs. Cytarabine Alone in Elderly Patients With Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Interventions: Drug: Arsenic trioxide;   Drug: Low-dose cytarabine alone
10 Unknown  Vorinostat Combined With Gemtuzumab Ozogamicin, Idarubicin and Cytarabine in Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Intervention: Drug: Salvage reinduction chemotherapy including Gemtuzumab ozogamicin, Idarubicin and Cytarabine and Vorinostat
11 Not yet recruiting Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Interventions: Drug: guadecitabine;   Drug: Treatment Choice (TC)
12 Recruiting Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia
Condition: Acute Myelogenous Leukemia
Intervention: Drug: Interleukin-2
13 Terminated Study of Troxatyl™ Administered by Continuous Infusion to Subjects With Refractory Acute Myelogenous Leukemia (AML)
Condition: Acute Myelogenous Leukemia
Intervention: Drug: Troxatyl™ (Cytotoxic Chemotherapeutic)
14 Not yet recruiting A Collaborative Palliative and Oncology Care Model for Patients With Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Interventions: Other: Standard Leukemia Care;   Other: Palliative Care
15 Recruiting A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Conditions: Acute Myeloid Leukemia, in Relapse;   Recurrent Adult Acute Myeloid Leukemia
Interventions: Drug: GO-203-2c;   Drug: GO-203-2c + Decitabine
16 Completed Pilot Study of Feasibility of Outpatient Daily High Dose Cytarabine as Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML)
Condition: Acute Myeloid Leukemia
Intervention: Drug: Cytarabine
17 Recruiting A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)
Condition: Acute Myeloid Leukemia
Intervention: Drug: AGS67E
18 Active, not recruiting Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Intervention: Drug: ASP2215
19 Withdrawn ALFA-0703 Study in Older Patients With Acute Myeloblastic Leukemia (AML)
Condition: Acute Myeloid Leukemia
Interventions: Drug: Vesanoid (ATRA);   Drug: AZACITIDINE (VIDAZA);   Drug: CYTARABINE
20 Completed A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old
Condition: Acute Myeloid Leukemia
Interventions: Drug: conventional chemotherapy (AraC + Daunorubicin),;   Drug: Mylotarg associated with conventional chemotherapy (AraC + Daunorubicin),

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.